Why Does CAR-T Treatment Require Experience? The Art of Finding the Right Balance

Summary: Drawing on extensive clinical experience, Dr. Su LI, Director of the Department of Hematology at GoBroad Shanghai Liquan Hospital, explains how CAR-T therapy works, how cytokine release syndrome (CRS) is assessed and managed, and how combination strategies may be used for high-risk patients. CAR-T treatment requires a delicate balance: insufficient expansion may limit efficacy, while excessive activation can increase the risk of serious adverse events. Through real-world cases, the article shows how experienced teams can adjust treatment in complex situations involving high-risk disease, older patients, and extramedullary lesions, with the goal of achieving deep responses while maintaining safety.

In recent years, CAR-T cell therapy has created new treatment possibilities for many patients with relapsed or refractory hematologic malignancies. But with this advanced treatment, sometimes described as a "living drug," success depends on much more than the day of cell infusion. It also relies on the medical team's ability to assess risk, monitor changes, manage complications, and make timely adjustments throughout the treatment process.

At a recent patient education session, Dr. Su LI, Director of the Department of Hematology and the Myeloma Center at GoBroad Shanghai Liquan Hospital, used real clinical cases to explain some of the complex science behind CAR-T therapy in a clear and practical way, helping patients and families understand why experience matters.

1. What Is CAR-T Therapy?

CAR-T is a form of cellular immunotherapy that uses genetic engineering to modify a patient's own T cells so they can recognize and attack specific tumor targets. In simple terms, the process has three main steps. First, T cells are collected from the patient. These immune cells are part of the body's natural defense system. Next, the cells are modified in the laboratory to express a chimeric antigen receptor, or CAR, which helps them recognize a specific target on tumor cells. Finally, the engineered CAR-T cells are infused back into the patient, where they can expand, identify target-bearing tumor cells, and help eliminate them.

2. Why Is CAR-T Treatment an Art of Balance?

Dr. Li explains that CAR-T treatment involves a delicate balance between efficacy and risk. Ideally, the infused cells expand enough in the body to control the tumor, but not so aggressively that they trigger severe treatment-related toxicity. Managing that balance is one of the areas where an experienced clinical team can make a major difference.

If CAR-T cells do not expand sufficiently, the antitumor effect may be limited. In this situation, the team may consider timely treatment adjustments to support a better response. On the other hand, excessive immune activation can lead to serious adverse events such as cytokine release syndrome (CRS) or neurotoxicity. Early recognition of warning signs, accurate grading, and timely intervention are therefore essential to patient safety.

3. How Is Cytokine Release Syndrome (CRS) Managed?

CRS is one of the most common adverse reactions associated with CAR-T therapy. Symptoms can include fever, fatigue, muscle aches, and other systemic effects. Some cases are mild, but severe CRS can become life-threatening if it is not recognized and treated promptly. To manage this risk, the team at GoBroad Shanghai Liquan Hospital uses a structured, stepwise approach across the treatment course:

• Clinical understanding: Using accumulated clinical experience to recognize how CRS may develop and progress;

• Early detection: Closely monitoring for subtle changes in symptoms and vital signs so warning signals can be identified as early as possible;

• Accurate grading: Assessing severity using internationally recognized criteria together with clinical judgment to guide the next treatment decision;

• Timely intervention: Providing individualized treatment and adjusting the approach dynamically to help patients move through the high-risk period as safely as possible.

4. High-Risk Patients Require Even More Clinical Experience

Patients with a high tumor burden or central nervous system involvement may face additional challenges during CAR-T therapy. In these more complex situations, experience matters at every stage: anticipating potential risks before treatment, preparing contingency plans, and responding quickly when unexpected problems arise. This overall clinical capability can help improve treatment benefit while protecting patient safety.

Breaking Through a Treatment Challenge: Extramedullary Relapse and Combination Therapy

Some patients with multiple myeloma develop extramedullary disease, meaning tumor deposits appear outside the bone marrow. In these cases, CAR-T therapy alone may not always provide sufficient control, and combination strategies may be considered. At GoBroad Shanghai Liquan Hospital, individualized approaches for extramedullary disease may include:

• CAR-T combined with radiotherapy to target localized extramedullary lesions;

• CAR-T combined with autologous hematopoietic stem cell transplantation, using complementary treatment approaches to deepen the overall response.

A Strong Start: Paying Close Attention to Cell Collection Quality

The starting material for CAR-T therapy is the patient's own T cells. Their number and functional quality can affect the manufacturing process and treatment outcome. For patients with relapsed or refractory disease, previous therapies may have reduced lymphocyte counts, making cell collection more challenging.

With extensive experience in cell collection, the Liquan team focuses on choosing the right collection window, making adjustments in advance when needed, and following standardized quality-control procedures to build a strong foundation for treatment from the very beginning.

Clinical Practice: Managing Complex Cases and Using Combination Strategies

Through several representative cases, Dr. Li illustrated how the team manages difficult situations involving high-risk disease, extramedullary involvement, and older patients.

When CAR-T cell expansion is insufficient or immune activation becomes excessive, close monitoring and flexible treatment adjustments may help patients move past these treatment challenges. For patients with large, high-risk extramedullary masses, carefully selected combination therapy can help control local disease. The team has also treated a 73-year-old patient with multiple underlying health conditions who achieved a deep response with acceptable treatment tolerance.

These cases highlight that CAR-T outcomes depend not only on the cell product itself, but also on how the entire treatment course is managed: anticipating risks, intervening at the right time, and understanding the differences between individual patients. This combination of clinical judgment and multidisciplinary care can help extend CAR-T treatment to some patients who may previously have been considered especially difficult to treat because of age, disease burden, or other risk factors.

CAR-T treatment is not a single event. It brings together advanced technology and day-to-day clinical decision-making. As Dr. Li emphasizes, an experienced team is important for finding the right balance between efficacy and safety, with the goal of helping each patient achieve the best possible and most durable treatment outcome.